Compugen : Peptide Drug Candidate for Treatment of Solid Tumor Cancers and Positive In Vivo Results

September 16, 2008 – Compugen Ltd. (NASDAQ: CGEN) announced that its proprietary DAC Blockers Discovery Platform has led to the discovery of CGEN-25008, a novel peptide antagonist of the Clusterin protein. Compugen also announced that recently analyzed in vitro and initial in vivo results from cell-based assays and a lung cancer mouse model indicate that CGEN-25008 reduces the growth rate of several cancer cell lines and significantly enhances the anti-cancer activity of Taxol™, a frequently used cancer chemotherapeutic drug.
Compugen’s DAC Blockers Platform was designed to predict peptides that can block proteins of interest from achieving certain disease-associated three-dimensional conformations. This discovery platform, announced in March 2008, is one of nine proprietary discovery platforms, to date, that have been developed and validated by Compugen for predictive discovery of drug and diagnostic product candidates... Compugen's Press Release -

Compugen : Discovery of Blood Based Biomarker for Diagnosis of Lung Cancer

April 29 2008 – Compugen Ltd. (NASDAQ: CGEN) announced the discovery and experimental verification of CGEN-438, a potential blood based biomarker for lung cancer. CGEN-438 is novel splice variant peptide of delta-like protein 3 precursor (DLL3). Importantly, the Compugen discovered biomarker is a peptide that is secreted from the cell into the bloodstream, whereas the previously known DLL3 is a protein located on the cell membrane. Initial clinical evidence indicates that the Compugen discovered molecule could potentially serve as both a serum biomarker for the diagnosis of small cell lung cancer and as a component in a biomarker combination for the diagnosis of non-small cell lung cancer patients... Compugen's Press Release -